NGF and cancer: Pan-Trk inhibitors like Larotrectinib are approved for rare TRK fusion-positive cancers, but preclinical studies using specific TrkA inhibitors or NGF-neutralizing antibodies have shown they can reduce the PNI potential of PDAC cells and inhibit neurite outgrowth (72).